TB-500 (Thymosin Beta-4)

Also known as Thymosin Beta-4

TB-500, the synthetic 43-amino-acid version of Thymosin Beta-4, accelerates tissue repair by upregulating actin polymerization, promoting cell migration, angiogenesis, and anti-inflammatory cytokine profiles—achieving 61% wound re-epithelialization by day 7 versus saline controls while preventing scar formation through collagen organization. It sequesters actin monomers to facilitate cytoskeletal remodeling essential for endothelial cell movement, fibroblast proliferation, and myocyte regeneration across skin, muscle, tendon, ligament, heart, and cornea.

Route

Subcutaneous injection

Dose range

500 mcg – 1 mg

Frequency

Once per day (subcutaneous)

Cycle length

8–12 weeks

TB-500 10MG
N1 AminosLab tested · CoA

TB-500 10MG

Third-party tested, lot traceable, ships in 3–5 business days.

$59.00per vial$50.00/vial at 10+
View →

Overview

TB-500, the synthetic 43-amino-acid version of Thymosin Beta-4, accelerates tissue repair by upregulating actin polymerization, promoting cell migration, angiogenesis, and anti-inflammatory cytokine profiles—achieving 61% wound re-epithelialization by day 7 versus saline controls while preventing scar formation through collagen organization. It sequesters actin monomers to facilitate cytoskeletal remodeling essential for endothelial cell movement, fibroblast proliferation, and myocyte regeneration across skin, muscle, tendon, ligament, heart, and cornea.

Research demonstrates reduced inflammation via prostaglandin EP4 and nitric oxide suppression, enhanced cardiac repair post-infarction, and peripheral nerve regeneration. Dosed subcutaneously (2-10mg weekly), users report faster injury recovery, improved flexibility, reduced joint pain, and systemic healing without fibrosis. For athletes, chronic injuries, or surgical recovery, TB-500 represents comprehensive tissue remodeling superior to growth factors alone.

Studied benefits

  • Promotes rapid wound healing, tissue repair, and the growth of new blood vessels (angiogenesis)
  • It is widely used in research and veterinary settings to reduce inflammation and prevent excessive scar tissue (fibrosis) after injury

Reported side effects

  • Generally well-tolerated
  • human data is limited, but research settings report only occasional mild redness or tenderness at the injection site

Protocol

Dosing Schedule (Subcutaneous)

Educational reference only. Not medical advice. Research compounds are not approved for human use. Full disclaimer.

TB-500 (5mg)

Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~1.67 mg/mL).

Support tissue repair, wound healing, and angiogenesis through the active thymosin beta-4 fragment mechanism.

TB-500 (10mg)

Reconstitute with 3.0 mL bacteriostatic water (Final concentration: ~3.33 mg/mL).

Support tissue repair, wound healing, and angiogenesis through the active thymosin beta-4 fragment mechanism.

PhaseDaily Dose (mcg)Draw at 1.67 mg/mLLog
Weeks 1–2500 mcg30 units (0.3 mL)+ Log
Weeks 3–4600 mcg36 units (0.36 mL)+ Log
Weeks 5–8750 mcg45 units (0.45 mL)+ Log
Weeks 9–121000 mcg60 units (0.6 mL)+ Log

Frequency

Once per day (subcutaneous).

Timing

Any consistent time daily; rotate injection sites.

Cycle length

8–12 weeks.

Unit calculator

Set your vial and water; the table above updates.

Open the full calculator →
Concentration

1.67 mg/mL

10 doses of 500 mcg per vial

At the starting dose (500 mcg × 7/week for a 8-week cycle) you would use about 28 mg, i.e. 6 × 5 mg vials. Higher phases use proportionally more.

Assumes a U-100 insulin syringe (100 units = 1 mL). Educational math only; verify every calculation yourself.

Context

Lifestyle considerations

Maintain a high-protein, balanced diet to provide the necessary substrate for the systemic tissue repair, wound healing, and angiogenesis promoted by this naturally occurring protein. Incorporate appropriate physical therapy or mobility-focused exercises to guide the remodeling of newly formed tissues and maintain joint flexibility during the recovery process. Ensure 7–9 hours of quality sleep to facilitate the deep-recovery phase where the peptide is most active at a cellular level. Practice stress management and maintain optimal hydration to reduce systemic oxidative stress, ensuring the healing environment is primed for cellular migration and regeneration.

Evidence

Research summaries

Thymosin Beta-4 Accelerates Wound Healing in Rat Full Thickness Wounds

Findings: Speeds up skin growth over wounds by 42-61%, boosts new blood vessel formation for better nutrient delivery, makes keratinocytes (skin cells) migrate to cover wounds faster.

TB-500, a fragment of thymosin beta-4, is nature's cell-movement maestro. In rats with big holes punched in their skin, topical or injected TB-500 closed wounds 42% faster by day 4, and up to 61% faster by day 7 compared to salt water. Why? It orchestrates keratinocyte (outer skin cell) migration—in tiny chambers, as little as 10 picograms (invisible amount!) sparked 2-3x more cell movement. Wounds also contracted (shrank) 11% more, a sign of healthy healing. Microscopy showed increased collagen and new blood vessels sprouting. Picture calling in construction workers with bulldozers—they arrive, move faster, and rebuild quicker. For burn victims, surgical wounds, or chronic non-healing ulcers (common in diabetics), TB-500 could cut healing time weeks shorter. Proof: reepithelialization measurements, contraction metrics, angiogenesis histology.

Read the study ↗

Muscle Injury-Induced Thymosin β4 Acts as a Chemoattractant for Myoblasts During Skeletal Muscle Regeneration

Findings: Pulls muscle-building cells to injury sites, speeds muscle repair after tears or strain, rebuilds lost muscle faster without atrophy (shrinking).

Ripped muscles spill out thymosin beta-4—the body's emergency flare gun. TB-500 works as a chemical trail, luring myoblasts (baby muscle cells) to the damaged area like ants to honey. In lab dishes, TB-500 accelerated wound closure and pumped up myoblast movement toward the peptide. mRNA tests showed TB-4 expression spiked early in muscle regeneration—the body's own signal for repair. For athletes post-injury or teens with muscle strains from sports, TB-500 mimics this natural signal, pulling healing cells in fast. Microscopy and migration assays proved dose-dependent cell attraction.

Read the study ↗

Thymosin Beta-4 Improves Endothelial Function and Reparative Capacity in Diabetic Ischemic Limb Disease

Findings: Grows new blood vessels in dead legs from diabetes, restores blood flow to prevent amputation, reduces cell death and aging in vessel linings.

Diabetic feet often can't heal—poor circulation kills tissue. TB-4 rescue team arrives: at 600 ng/mL, it supercharged endothelial cells (blood vessel linings) in diabetic models. Cell survival jumped (Bcl-XL up), aging markers dropped, and vessel-formation capacity (angiogenic potency) soared. In mice with bad circulation from diabetes, TB-4-treated endothelial cells grafted onto ischemic (starved) limbs improved blood vessel density and foot function—mice could walk better. The peptide cuts bad signals (endothelin-1, MMP-1 tissue destroyers) while cranking up pro-survival pathways (AKT). Under low-oxygen stress (simulating gangrene), TB-4 cells survived 3+ hours vs. controls dying fast. For teens at diabetes risk or with circulation problems, TB-500 could prevent amputations by regrow­ing circulation decades early. Proof: Western blots, flow cytometry, angiogenesis assays, in vivo perfusion studies.

Read the study ↗
More references (4)

Identification

Chemistry

cas
885340-08-9 (TB-500 fragment free base); 77591-33-4 (full-length thymosin beta-4)
formula
C₃₈H₆₈N₁₀O₁₄ (TB-500 fragment); C₂₁₂H₃₅₀N₅₆O₇₈S (full thymosin beta-4)
molecular weight
889.02 g/mol (TB-500 fragment); 4963.44 g/mol (full thymosin beta-4)
sequence
Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln (N-terminal acetyl group, eight amino acids: leucine, lysine, lysine, threonine, glutamic acid, threonine, glutamine)
source
Synthetic; derived from naturally occurring thymosin beta-4
biosynthesis
Non-ribosomal; chemically synthesized via solid-phase peptide synthesis (SPPS) with N-terminal acetylation
type
Linear octapeptide with N-terminal acetylation; free C-terminal carboxylic acid

Keep exploring

Related peptides

Educational use only. The protocols shown summarise published research and community practice for informational purposes. They are not medical advice, not a prescription, and not a recommendation to use any compound. Research peptides are generally not approved for human use. Consult a licensed clinician. Full disclaimer.
Ask the advisor